Phase I clinical trial of a novel procaspase-3 activator SM-1 with temozolomide in recurrent high-grade gliomas [0.03%]
SM-1与替莫唑胺联合治疗复发高级别胶质瘤的I期临床试验
Mengqian Huang,Zhuang Kang,Shenglan Li et al.
Mengqian Huang et al.
Objective: Despite a standard of care, the mortality of recurrent high-grade gliomas (HGGs) remains high. SM-1 is a novel molecular activator that has shown to target procaspase-3, which is overexpressed in HGGs. A phase ...
MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability [0.03%]
MYH基因敲低使胰腺癌细胞产生可利用的DNA修复弱点
James Ephraums,Janet Youkhana,Aparna S Raina et al.
James Ephraums et al.
Pancreatic ductal adenocarcinoma (PDAC) has a poor 5-year survival rate of just 13 %. Conventional therapies fail due to acquired chemoresistance. We previously identified MutY-Homolog (MYH), a protein that repairs oxidative DNA damage, as ...
Identification of 68 HLA-A24 and -A2-restricted cytotoxic T lymphocyte-inducing peptides derived from 10 common cancer-specific antigens frequently expressed in various solid cancers [0.03%]
基于肿瘤常见特异性抗原鉴定HLA-A24和-A2限制的CTL表位肽及在多种实体瘤中表达分布情况的研究
Hiroki Kinoshita,Kazumasa Takenouchi,Nobuo Tsukamoto et al.
Hiroki Kinoshita et al.
Targeting cancer antigens expressed in cancer cells is necessary to develop cancer-specific immunotherapy. We have performed immunohistochemical analysis of various solid cancer specimens, adding ROBO1, AFP, TGFBI, EphB4, CLDN1, and LAT1 to...
Disruption of redox balance in glutaminolytic triple negative breast cancer by inhibition of glutaminase and glutamate export [0.03%]
通过抑制谷氨酰胺酶和谷氨酸外排打断谷氨酰胺依赖的三阴性乳腺癌细胞内的氧化还原平衡
Hoon Choi,Mamta Gupta,Arjun Sengupta et al.
Hoon Choi et al.
Resistance to chemotherapy is an important challenge in the clinical management of triple-negative breast cancer (TNBC). Utilization of the amino acid glutamine as a key nutrient is a metabolic signature of TNBC featuring high glutaminase (...
STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes [0.03%]
急性髓系白血病和骨髓增生异常综合征的发病机制及治疗中的STAT信号通路功能研究
Zoe King,Sudhamsh Reddy Desai,David A Frank et al.
Zoe King et al.
Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) represent complex hematopoietic malignancies characterized by ineffective hematopoiesis and dysregulated myeloid differentiation. Recent research has underscored the critical ...
The Impact of Atorvastatin on Intraprostatic Biomarkers - Prognostic Value of 3LS-score - Follow-up of ESTO1-Trial [0.03%]
阿托伐他汀对前列腺组织生物标志物的影响及3LS评分的预后价值-ESTO1研究的随访结果
Eemil Lehtonen,Maiju Vertanen,Heimo Syvälä et al.
Eemil Lehtonen et al.
Background: Prostate cancer (PCa) remains a global health burden, with limited reliable biomarkers beyond prostate-specific antigen (PSA). Statins have been associated with survival benefits in advanced Pca, potentially b...
Cancer stem-like cells stay in a plastic state ready for tumor evolution [0.03%]
癌干细胞保持一种可塑性状态以备肿瘤进化之需
Jiali Xu,Houde Zhang,Zhihao Nie et al.
Jiali Xu et al.
Cell plasticity emerges as a novel cancer hallmark and is pivotal in driving tumor heterogeneity and adaptive resistance to different therapies. Cancer stem-like cells (CSCs) are considered the root of cancer. While first defined as tumor-i...
An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors [0.03%]
一项开放标签研究以确定单药口服ESK-440在晚期或转移性实体瘤患者中的最大耐受剂量
Russell J Schilder,Drew Rasco,Manish R Sharma
Russell J Schilder
Purpose: Anaplastic lymphoma kinase (ALK) dysregulation is implicated in numerous cancers. Tyrosine kinase inhibitors (TKIs) targeting ALK have improved disease outcomes, but resistance mechanisms are common. This first-i...
YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2Y641mut germinal center-derived lymphoma [0.03%]
YPEL2调节BRD4-EZH2联合抑制在EZH2Y641突变型滤泡中心衍生淋巴瘤中的疗效
Aránzazu Chamorro-Jorganes,Núria Profitós-Pelejà,Clara Recasens-Zorzo et al.
Aránzazu Chamorro-Jorganes et al.
A significant proportion of diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) cases harbor a gain-of-function, heterozygous somatic mutation of the methyltransferase gene EZH2. While this factor is known to cooperate with t...
SLC31A1 promotes chemoresistance through inducing CPT1A-mediated fatty acid oxidation in ER-positive breast cancer [0.03%]
SLC31A1通过诱导ER阳性乳腺癌中CPT1A介导的脂肪酸氧化促进化疗耐药性
Xudong Li,Jingjing Ge,Mengdi Wan et al.
Xudong Li et al.
Over 60% of breast cancer cases are diagnosed with estrogen-receptor (ER) positive. Tamoxifen (TAM), a commonly employed medication for ER-positive breast cancer, often yields suboptimal therapeutic outcomes due to the emergence of TAM resi...